Compare Procter & Gamble Health with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs VENUS REMEDIES - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH VENUS REMEDIES PROCTER & GAMBLE HEALTH/
VENUS REMEDIES
 
P/E (TTM) x 41.9 -2.8 - View Chart
P/BV x 4.5 0.2 2,420.8% View Chart
Dividend Yield % 10.6 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   VENUS REMEDIES
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
VENUS REMEDIES
Mar-18
PROCTER & GAMBLE HEALTH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,549126 2,818.9%   
Low Rs1,30161 2,129.8%   
Sales per share (Unadj.) Rs511.4301.8 169.5%  
Earnings per share (Unadj.) Rs61.3-24.9 -246.4%  
Cash flow per share (Unadj.) Rs74.02.5 2,908.6%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.8293.3 316.3%  
Shares outstanding (eoy) m16.6012.34 134.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,530.5%   
Avg P/E ratio x39.6-3.8 -1,052.5%  
P/CF ratio (eoy) x32.836.7 89.2%  
Price / Book Value ratio x2.60.3 819.9%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,2571,154 3,489.2%   
No. of employees `0001.10.9 122.6%   
Total wages/salary Rs m1,313393 333.9%   
Avg. sales/employee Rs Th7,486.74,026.1 186.0%   
Avg. wages/employee Rs Th1,157.6425.0 272.4%   
Avg. net profit/employee Rs Th897.2-331.8 -270.4%   
INCOME DATA
Net Sales Rs m8,4903,724 228.0%  
Other income Rs m24423 1,084.0%   
Total revenues Rs m8,7343,747 233.1%   
Gross profit Rs m1,482395 375.3%  
Depreciation Rs m211338 62.4%   
Interest Rs m0354 0.0%   
Profit before tax Rs m1,514-275 -550.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m56332 1,780.1%   
Profit after tax Rs m1,017-307 -331.5%  
Gross profit margin %17.510.6 164.6%  
Effective tax rate %37.1-11.5 -323.6%   
Net profit margin %12.0-8.2 -145.4%  
BALANCE SHEET DATA
Current assets Rs m15,3432,638 581.7%   
Current liabilities Rs m1,9602,305 85.1%   
Net working cap to sales %157.68.9 1,762.7%  
Current ratio x7.81.1 683.9%  
Inventory Days Days49135 36.0%  
Debtors Days Days2846 61.4%  
Net fixed assets Rs m1,2094,871 24.8%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m15,2353,496 435.8%   
Net worth Rs m15,4013,619 425.6%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m17,5957,509 234.3%  
Interest coverage xNM0.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.5 97.3%   
Return on assets %5.80.6 916.0%  
Return on equity %6.6-8.5 -77.9%  
Return on capital %10.31.6 648.4%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m1,6360-   
Fx outflow Rs m4,368517 845.7%   
Net fx Rs m-2,732-517 528.9%   
CASH FLOW
From Operations Rs m-1,304514 -253.5%  
From Investments Rs m12,697-123 -10,314.5%  
From Financial Activity Rs m-301-387 77.6%  
Net Cashflow Rs m11,0934 264,116.7%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.2 10,111.1%  
FIIs % 1.0 0.6 172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 66.4 43.8%  
Shareholders   28,591 20,121 142.1%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Jul 10, 2020 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS